C
Carol I. Lord
Researcher at Beth Israel Deaconess Medical Center
Publications - 34
Citations - 3367
Carol I. Lord is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Simian immunodeficiency virus & Virus. The author has an hindex of 27, co-authored 34 publications receiving 3348 citations. Previous affiliations of Carol I. Lord include Harvard University.
Papers
More filters
Journal ArticleDOI
Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination.
Norman L. Letvin,David C. Montefiori,Yasuhiro Yasutomi,Helen C. Perry,Mary-Ellen Davies,Christine Lekutis,Marianne Alroy,Daniel C. Freed,Carol I. Lord,Laurence K. Handt,Margaret A. Liu,John W. Shiver +11 more
TL;DR: The addition of HIV-1 Env protein to this regimen as a boosting immunogen generates a high titer neutralizing antibody response in this nonhuman primate species, suggesting that a DNA prime/DNA plus protein boost regimen warrants active investigation as a vaccine strategy to prevent HIV- 1 infection.
Journal Article
Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys.
Marcelo J. Kuroda,Jörn E. Schmitz,William A. Charini,Christine E. Nickerson,Michelle A. Lifton,Carol I. Lord,Meryl A. Forman,Norman L. Letvin +7 more
TL;DR: The CTL response was characterized during primary SIV/macaque infection of rhesus monkeys to assess its role in containing early viral replication using both an epitope-specific functional and an MHC class I/peptide tetramer-binding assay, suggesting that CTL may be important in containing virus replication.
Journal Article
Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.
TL;DR: This model system can be used to evaluate the efficacy of anti-HIV-1 vaccines directed at the envelope glycoproteins,Anti-Hiv-1 envelope glyCoprotein antiserum or monoclonal antibodies, and anti-hIV- 1 drugs designed to inhibit the tat, rev, or env functions.
Journal ArticleDOI
New recombinant HLA-B alleles in a tribe of South American Amerindians indicate rapid evolution of MHC class I loci
David I. Watkins,Stephen N. McAdam,Xiaomin Liu,Clarice R. Strang,Edgar L. Milford,Cindy G. Levine,Theodore L. Garber,Alex L. Dogon,Carol I. Lord,Steven H. Ghim,Gary M. Troup,Austin L. Hughes,Norman L. Letvin +12 more
TL;DR: Analysis of the class I alleles of the Waorani of South America and the Zuni of North America indicates that the HLA-B locus can evolve rapidly in isolated populations and underline the importance of gathering genetic data on endangered native human populations.
Journal ArticleDOI
A cytotoxic T lymphocyte inhibits acquired immunodeficiency syndrome virus replication in peripheral blood lymphocytes.
TL;DR: It is suggested that the cell that inhibits AIDS virus replication in PBL of infected individuals is a CTL, suggesting they may be antigen-specific T cells.